Gilead expands Tango alliance, continuing a busy year of cancer deals

Gilead expanded a 2018 deal with privately held Tango Therapeutics, announcing it has added up to 10 potential oncology targets to the five the big biotech already agreed to option for development. Tango will receive $125 million in cash and will sell $20 million worth of shares to Gilead.